vs
Side-by-side financial comparison of Tilray Brands, Inc. (TLRY) and USANA HEALTH SCIENCES INC (USNA). Click either name above to swap in a different company.
Tilray Brands, Inc. is the larger business by last-quarter revenue ($217.5M vs $213.7M, roughly 1.0× USANA HEALTH SCIENCES INC). USANA HEALTH SCIENCES INC runs the higher net margin — -3.1% vs -20.7%, a 17.6% gap on every dollar of revenue. On growth, USANA HEALTH SCIENCES INC posted the faster year-over-year revenue change (6.7% vs 3.1%). Over the past eight quarters, Tilray Brands, Inc.'s revenue compounded faster (7.5% CAGR vs -1.7%).
Tilray Brands, Inc. is an American pharmaceutical, cannabis-lifestyle and consumer packaged goods company, incorporated in the United States, headquartered in New York City. Tilray also has operations in Canada, Australia, New Zealand, and Latin America, with growing facilities in Germany and Portugal.
Usana Health Sciences, Inc., or USANA, is an American multi-level marketing company based in Salt Lake City, Utah. As of 2021, Usana was the 14th largest direct-selling company in the world by revenue. The company manufactures most of its nutritional products, dietary supplements, and skincare products at a Salt Lake City facility. Its products are sold in 24 countries via a network of independent distributors.
TLRY vs USNA — Head-to-Head
Income Statement — Q2 2026 vs Q3 2026
| Metric | | |
|---|---|---|
| Revenue | $217.5M | $213.7M |
| Net Profit | $-44.9M | $-6.5M |
| Gross Margin | 26.4% | 77.2% |
| Operating Margin | -10.2% | 0.6% |
| Net Margin | -20.7% | -3.1% |
| Revenue YoY | 3.1% | 6.7% |
| Net Profit YoY | 47.4% | -161.5% |
| EPS (diluted) | $-0.41 | $-0.36 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $217.5M | — | ||
| Q3 25 | $209.5M | $213.7M | ||
| Q2 25 | $224.5M | $235.8M | ||
| Q1 25 | $185.8M | $249.5M | ||
| Q4 24 | $210.9M | $213.6M | ||
| Q3 24 | $200.0M | $200.2M | ||
| Q2 24 | $229.9M | $212.9M | ||
| Q1 24 | $188.3M | $227.8M |
| Q4 25 | $-44.9M | — | ||
| Q3 25 | $-322.0K | $-6.5M | ||
| Q2 25 | $-1.3B | $9.7M | ||
| Q1 25 | $-789.4M | $9.4M | ||
| Q4 24 | $-85.3M | $4.5M | ||
| Q3 24 | $-39.2M | $10.6M | ||
| Q2 24 | $-31.7M | $10.4M | ||
| Q1 24 | $-92.7M | $16.5M |
| Q4 25 | 26.4% | — | ||
| Q3 25 | 27.4% | 77.2% | ||
| Q2 25 | 30.1% | 78.7% | ||
| Q1 25 | 28.0% | 79.0% | ||
| Q4 24 | 29.0% | 82.0% | ||
| Q3 24 | 29.8% | 80.4% | ||
| Q2 24 | 35.8% | 81.1% | ||
| Q1 24 | 26.2% | 81.1% |
| Q4 25 | -10.2% | — | ||
| Q3 25 | 1.0% | 0.6% | ||
| Q2 25 | -643.1% | 7.1% | ||
| Q1 25 | -409.0% | 6.3% | ||
| Q4 24 | -20.0% | 3.8% | ||
| Q3 24 | -18.3% | 7.8% | ||
| Q2 24 | -7.2% | 8.4% | ||
| Q1 24 | -43.6% | 10.8% |
| Q4 25 | -20.7% | — | ||
| Q3 25 | -0.2% | -3.1% | ||
| Q2 25 | -566.9% | 4.1% | ||
| Q1 25 | -424.9% | 3.8% | ||
| Q4 24 | -40.5% | 2.1% | ||
| Q3 24 | -19.6% | 5.3% | ||
| Q2 24 | -13.8% | 4.9% | ||
| Q1 24 | -49.2% | 7.3% |
| Q4 25 | $-0.41 | — | ||
| Q3 25 | $0.00 | $-0.36 | ||
| Q2 25 | $7.26 | $0.52 | ||
| Q1 25 | $-8.69 | $0.49 | ||
| Q4 24 | $-0.99 | $0.23 | ||
| Q3 24 | $-0.04 | $0.56 | ||
| Q2 24 | $-0.04 | $0.54 | ||
| Q1 24 | $-0.12 | $0.86 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $291.6M | $145.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.6B | $528.1M |
| Total Assets | $2.1B | $726.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $291.6M | — | ||
| Q3 25 | $264.8M | $145.3M | ||
| Q2 25 | $256.4M | $151.3M | ||
| Q1 25 | — | $179.6M | ||
| Q4 24 | $252.2M | $181.8M | ||
| Q3 24 | $280.1M | $364.9M | ||
| Q2 24 | $260.5M | $332.4M | ||
| Q1 24 | $225.9M | $328.3M |
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.5B | $528.1M | ||
| Q2 25 | $1.5B | $531.1M | ||
| Q1 25 | $2.7B | $529.8M | ||
| Q4 24 | $3.5B | $532.1M | ||
| Q3 24 | $3.5B | $533.1M | ||
| Q2 24 | $3.4B | $512.2M | ||
| Q1 24 | $3.4B | $500.0M |
| Q4 25 | $2.1B | — | ||
| Q3 25 | $2.1B | $726.6M | ||
| Q2 25 | $2.1B | $734.5M | ||
| Q1 25 | — | $746.6M | ||
| Q4 24 | $4.2B | $748.2M | ||
| Q3 24 | $4.3B | $671.3M | ||
| Q2 24 | $4.2B | $631.4M | ||
| Q1 24 | $4.2B | $629.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-8.5M | $-2.0M |
| Free Cash FlowOCF − Capex | — | $-5.2M |
| FCF MarginFCF / Revenue | — | -2.4% |
| Capex IntensityCapex / Revenue | — | 1.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $18.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-8.5M | — | ||
| Q3 25 | $-1.3M | $-2.0M | ||
| Q2 25 | $-12.8M | $12.2M | ||
| Q1 25 | $-5.8M | $15.5M | ||
| Q4 24 | $-40.7M | $5.8M | ||
| Q3 24 | $-35.3M | $29.5M | ||
| Q2 24 | $30.7M | $8.0M | ||
| Q1 24 | $-15.4M | $17.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | $-5.2M | ||
| Q2 25 | $-19.1M | $7.2M | ||
| Q1 25 | $-20.2M | $12.7M | ||
| Q4 24 | $-46.2M | $4.0M | ||
| Q3 24 | $-42.0M | $27.1M | ||
| Q2 24 | $21.0M | $5.3M | ||
| Q1 24 | $-24.9M | $14.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | -2.4% | ||
| Q2 25 | -8.5% | 3.0% | ||
| Q1 25 | -10.9% | 5.1% | ||
| Q4 24 | -21.9% | 1.9% | ||
| Q3 24 | -21.0% | 13.6% | ||
| Q2 24 | 9.1% | 2.5% | ||
| Q1 24 | -13.2% | 6.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.5% | ||
| Q2 25 | 2.8% | 2.1% | ||
| Q1 25 | 7.8% | 1.1% | ||
| Q4 24 | 2.6% | 0.8% | ||
| Q3 24 | 3.4% | 1.2% | ||
| Q2 24 | 4.2% | 1.3% | ||
| Q1 24 | 5.1% | 1.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 1.27× | ||
| Q1 25 | — | 1.65× | ||
| Q4 24 | — | 1.29× | ||
| Q3 24 | — | 2.78× | ||
| Q2 24 | — | 0.77× | ||
| Q1 24 | — | 1.07× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TLRY
| Adultuse Cannabis Products | $62.4M | 29% |
| Other | $59.2M | 27% |
| Beverage Alcohol Business | $53.6M | 25% |
| International Cannabis Products | $20.2M | 9% |
| Wellness Business | $14.6M | 7% |
| Medical Cannabis Products | $6.2M | 3% |
| Wholesale Cannabis Products | $1.3M | 1% |
USNA
| Direct Selling | $175.8M | 82% |
| Hiya | $30.8M | 14% |
| All Other | $7.0M | 3% |
